Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 8,572 | -22,948 | -15,566 | -13,866 | -68,566 |
| Depreciation Amortization | N/A | N/A | N/A | N/A | 2 |
| Accounts receivable | 24,032 | 48,523 | 24,938 | 25,780 | 46,351 |
| Accounts payable and accrued liabilities | -6,613 | -5,911 | -6,526 | -5,541 | 5,928 |
| Other Working Capital | -27,156 | 13,936 | -8,950 | 8,035 | 36,284 |
| Other Operating Activity | -11,459 | -37,873 | -15,591 | -18,410 | -43,443 |
| Operating Cash Flow | $-12,624 | $-4,273 | $-21,695 | $-4,002 | $-23,444 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Financing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Beginning Cash Position | 52,889 | 52,889 | 52,889 | 52,889 | 76,333 |
| End Cash Position | 40,265 | 48,616 | 31,194 | 48,887 | 52,889 |
| Net Cash Flow | $-12,624 | $-4,273 | $-21,695 | $-4,002 | $-23,444 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,624 | -4,273 | -21,695 | -4,002 | -23,444 |
| Free Cash Flow | -12,624 | -4,273 | -21,695 | -4,002 | -23,444 |